Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study

Jingping Zhao,1,* Lehua Li,1,* Jianguo Shi,2 Yi Li,3 Xiufeng Xu,4 Keqing Li,5 Lili Zhang,6 Shangli Cai,6 Yu Feng,6 Jianmin Zhuo,6 Weihong Liu,6 Huafei Lu6 1Department of Psychiatry, The Mental Health Institute, The Second Xiangya Hospital of Central South University, 2Department of Psychiatry, Ment...

Full description

Bibliographic Details
Main Authors: Zhao JP, Li LH, Shi JG, Li Y, Xu XF, Li KQ, Zhang LL, Cai SL, Feng Y, Zhuo JM, Liu WH, Lu HF
Format: Article
Language:English
Published: Dove Medical Press 2017-08-01
Series:Neuropsychiatric Disease and Treatment
Subjects:
Chinese
long-acting injectables
open-label
paliperidone palmitate
PANSS
schizophrenia
Online Access:https://www.dovepress.com/safety-and-efficacy-of-paliperidone-palmitate-1-month-formulation-in-c-peer-reviewed-article-NDT

Internet

https://www.dovepress.com/safety-and-efficacy-of-paliperidone-palmitate-1-month-formulation-in-c-peer-reviewed-article-NDT

Similar Items